Will big pharma gobble this one up next?
or less...no one wants to be another OPTR shareholder. Not sure Drtx can compete here?
Big pharma owned that antibiotic just 3 years ago. They sold it off for pocket change after seeing the P3 data from earlier trials and having the FDA reject the application 3 times.
But it might well get a trading pop tomorrow.